Bristol-Myers Squibb Co. has completed its acquisition of Celgene Corp. following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, approval by Bristol-Myers Squibb and Celgene stockholders. It completed the acquisition Nov. 20.
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
